PANX1 and neoplasm: From a therapeutic standpoint, Panx1 has been linked to the proinflammatory release of ATP from tumor cells treated with immunogenic cell death (ICD) inducing agents like anthracyclines and oxaliplatin (Wang et al., 2013c; Martins et al., 2014).